Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | CA12 | O43570 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 6/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469041 | 0.91 | TDP1 (0.47) | TDP1AKT1CA1CA2CA12 | |
| SCHEMBL17254414 | 0.80 | MEN1 (0.55) | TDP1AKT1CA1CA2CA12 | |
| SCHEMBL31509615 | 0.78 | MEN1 (0.59) | TDP1AKT1CA1CA2CA12 | |
| SCHEMBL17527990 | 0.75 | GAA (0.51) | TDP1AKT1CA1CA2CA12 | |
| SCHEMBL20650891 | 0.75 | GAA (0.51) | TDP1AKT1CA1CA2CA12 | |
| SCHEMBL7801592 | 0.75 | TDP1 (0.56) | TDP1AKT1CA1CA2CA12 | |
| SCHEMBL17738032 | 0.75 | TDP1 (0.56) | TDP1AKT1CA1CA2CA12 | |
| SCHEMBL25935501 | 0.75 | TDP1 (0.56) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL28508194 | 0.75 | TDP1 (0.56) | TDP1AKT1CA1CA2CA12 | |
| SCHEMBL27317330 | 0.75 | TDP1 (0.56) | TDP1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-118591393-A | Antibody conjugated chemical degradation inducers with hydrolyzable maleimide linkers and methods thereof | 基因泰克公司 | 2024-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | LGMN, B2M, HNMT | TDP1 2839/4885AKT1 4238/4885CA1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.